Related Experiment Video

Updated: Jul 7, 2026

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Genetic variability in hepatitis C virus and its role in antiviral treatment response

M Torres-Puente1, J M Cuevas, N Jiménez-Hernández

  • 1Departamento de Genética, Universidad de Valencia, Valencia, Spain.

Journal of Viral Hepatitis
|February 1, 2008
PubMed

Insights

Hepatitis C virus (HCV) genetic variability influences treatment response. Higher viral genetic diversity was observed in non-responders compared to responders to alpha interferon and ribavirin therapy.

Area of Science:

  • Virology
  • Genetics
  • Hepatology

Background:

  • Hepatitis C virus (HCV) affects 170 million globally, with genetic variability contributing to chronic infection.
  • Understanding HCV genetic diversity is crucial for predicting treatment outcomes.
  • Combined therapy with alpha interferon and ribavirin is a standard treatment approach.

Purpose of the Study:

  • To analyze the genetic variability of HCV in patients before combined antiviral therapy.
  • To investigate the correlation between HCV genetic diversity and treatment response (responder vs. non-responder).
  • To identify specific genetic markers associated with treatment outcomes.

Main Methods:

  • Large-scale sequence analysis of HCV genotype 1 (subtypes 1a and 1b) from 67 patients.
  • Analysis of two specific HCV genome regions: hypervariable regions (HVR1-3) of E2 glycoprotein and interferon-sensitive determining region (ISDR)/V3 domain of NS5A protein.
  • Comparison of genetic diversity measures and amino acid composition between responder and non-responder groups.

Main Results:

  • Higher genetic variability was observed in non-responder patients compared to responder patients.
  • Amino acid composition revealed subtype-specific variants but no single position discriminated between responders and non-responders.
  • Most amino acid positions were highly conserved, particularly in subtype 1a.

Conclusions:

  • HCV treatment outcome likely depends on the combined effect of multiple genetic positions, not just one or two.
  • Host immune response plays a significant role in treatment success, alongside antiviral therapy.
  • Further research into complex genetic interactions and host factors is warranted for optimizing HCV treatment.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...